Core Insights - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating Akero Therapeutics, Inc. regarding its proposed sale to Novo Nordisk A/S, which offers Akero shareholders $54.00 per share in cash and a contingent value right of $6.00 per share upon regulatory approval of efruxifermin by June 30, 2031 [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm is located in the Empire State Building, New York City, and specializes in national class action securities litigation [2] Transaction Details - The proposed transaction involves Akero shareholders receiving a total of $60.00 per share, contingent upon regulatory approval, raising questions about the fairness of the deal [1]

We recently published 10 Big Names With Whopping Gains; 6 Jump All-Time Highs. Akero Therapeutics, Inc. (NASDAQ:AKRO) is one of the best performers on Thursday. Akero Therapeutics saw its share prices jump by 16.33 percent on Thursday to end at $54.08 apiece following announcements that it was set to merge with Novo Nordisk in a $5.2 billion deal. In a statement, Akero Therapeutics, Inc. (NASDAQ:AKRO) said both companies officially entered into a definitive agreement, under which Novo Nordisk would acqui ...

Key Points It agreed to be acquired by a high-profile pharmaceutical company. The buyout could be worth as much as $5.2 billion. 10 stocks we like better than Akero Therapeutics › One of the best catalysts for sudden, sharp rise in the price of a stock is when the company behind it get acquired at a premium. Case in point: Akero Therapeutics (NASDAQ: AKRO), whose shares soared by more than 16% Thursday after it was revealed the biotech will have a new owner. That pop was especially impressive, give ...

Core Insights - Akero Therapeutics is currently involved in a significant transaction with Novo Nordisk, which has attracted attention from law firms investigating potential legal violations and the fairness of the sale [1][5][6] Financial Overview - Canaccord Genuity has set a price target of $54 for Akero, which aligns with the trading price and the per-share sale price to Novo Nordisk, valuing Akero at approximately $4.7 billion [2][6] - The stock is trading at $54.25, reflecting a 16.68% increase or $7.76, indicating positive market sentiment towards the transaction [3][6] - Akero's market capitalization is approximately $4.34 billion, with a trading volume of 27.07 million shares [4] Legal and Regulatory Aspects - Investigations by Ademi Firm and Halper Sadeh LLC are focusing on potential breaches of fiduciary duty and the fairness of the proposed sale, raising questions about the implications for Akero's shareholders [5][6] - The transaction includes substantial benefits for Akero insiders and imposes penalties if Akero accepts a competing bid, which limits alternative transactions [4]

Core Viewpoint - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion to obtain its promising drug efruxifermin for treating metabolic-associated steatotic liver disease (MASH) [1][3] Group 1: Acquisition Details - The acquisition price is set at $54 per share in cash, representing a 16% premium over Akero's closing price of $46.49 [3] - If efruxifermin receives full approval in the U.S. by June 30, 2031, Novo Nordisk will pay an additional $6 per share to Akero shareholders as a contingent value right (CVR) [3] - Following the announcement, Akero's stock surged over 19% in pre-market trading, while Novo Nordisk's stock fell nearly 2% [3] Group 2: Strategic Importance - Efruxifermin is currently in late-stage clinical trials for patients with severe liver scarring due to MASH, which is closely linked to obesity [5] - Novo Nordisk views efruxifermin as a potential cornerstone therapy for MASH, which can be used alone or in combination with its weight-loss drug Wegovy [4][5] - The acquisition aligns with Novo Nordisk's strategy to enhance its product pipeline in the competitive obesity treatment market, especially against rivals like Eli Lilly [6] Group 3: Market Context - The MASH market is becoming increasingly important, with major pharmaceutical companies actively pursuing acquisitions to strengthen their positions [5] - Recent transactions in the sector include Roche's agreement to acquire 89Bio Inc. for up to $3.5 billion and GlaxoSmithKline's acquisition of a potential MASH treatment for up to $2 billion [5] - Novo Nordisk's new CEO, Mike Doustdar, emphasizes focusing on developing next-generation obesity and diabetes drugs that also address MASH and related cardiovascular metabolic diseases [6]

By Maggie Fick and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish drugmaker's new CEO to spur growth. Mike Doustdar, who took the helm at the Wegovy maker in July, has signaled a focus on new, highly effective obesity and diabetes drugs that can also treat related cardiometabolic conditions such as MASH, rather than expanding into other ...

, /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Akero will receive $54.00 per share, representing an equity value of approximately $4.7 billion. Shareholders will also receive a c ...

诺和诺德同意以高达52亿美元的价格收购美国生物技术公司Akero Therapeutics，旨在获取后者一款前景广阔的肝病药物，从而在与肥胖相关的代 谢性疾病治疗领域加码布局，以应对日益激烈的市场竞争。 周四，这家丹麦制药巨头宣布，将以每股54美元的现金预付款收购Akero，这较Akero周三46.49美元的收盘价溢价约16%。根据协议，如果该药 物在2031年6月30日前就相关适应症获得美国全面批准，诺和诺德还将向Akero股东支付每股6美元的额外款项，即所谓的或有价值权（CVR）。 这是诺和诺德新任首席执行官Mike Doustdar自7月上任以来的首个重大交易，凸显其提振销售增长、抵御来自美国竞争对手礼来压力的决心。交 易消息公布后，市场反应迅速：Akero股价在盘前交易中跃升超过19%，而诺和诺德股价则下跌近2%。 Mike Doustdar在一份声明中表示，Akero的在研药物有潜力成为治疗代谢功能障碍相关脂肪性肝炎（MASH）的"基石"疗法，既可单独使用，也可 与诺和诺德的重磅减肥药Wegovy联合使用。 诺和诺德方面认为，efruxifermin有潜力成为首个能够逆转MASH相关终末期肝损伤的疗 ...

RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Novo Nordisk to acquire Akero Therapeutics Inc. 2 Investor presentation 9 October 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2024, Form 20-F, any quarterly financial reports, investor presentations and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the ope ...

STOCKHOLM (Reuters) -Novo Nordisk (NVO) said on Thursday it would buy U.S.-based Akero Therapeutics (AKRO) for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth. Shares of Akero jumped more than 18% in premarket trading, while Novo's Denmark-listed shares were down nearly 2%. The deal underscores new Novo Nordisk CEO Mike Doustdar's efforts to revive sales growth and fend off intense competition from U.S. riv ...